eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
2/2015
vol. 66
 
Share:
Share:
more
 
 
abstract:

Original paper
Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting

Agnieszka Adamczyk
,
Joanna Niemiec
,
Anna Janecka
,
Agnieszka Harazin-Lechowska
,
Aleksandra Ambicka
,
Aleksandra Grela-Wojewoda
,
Małgorzata Domagała-Haduch
,
Ida Cedrych
,
Kaja Majchrzyk
,
Anna Kruczak
,
Janusz Ryś
,
Jerzy Jakubowicz

Pol J Pathol 2015; 66 (2): 133-141
Online publish date: 2015/07/28
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Resistance to trastuzumab in patients with HER2-overexpressing breast cancer is associated with higher risk of progression or cancer death, and might be related to activation of PI3K/AKT/mTOR and Ras/Raf/MAPK signaling cascades and a decreased level of their inhibitor (PTEN).

HER2-overexpressing breast cancer patients (n = 75) treated with radical local therapy and trastuzumab in adjuvant setting were included into the study. Deoxyribonucleic acid isolated from paraffin sections was used to assess mutational status of the PIK3CA gene (p.H1047R and p.E545K mutations) by the quantitative polymerase chain reaction technique. Expression of selected proteins (ER, PgR, AR, Ki-67, EGFR) was assessed using immunohistochemistry.

In the studied group we found significantly higher Ki-67LI in EGFR-positive carcinomas (p = 0.048). Moreover, EGFR immunonegativity was observed more frequently in low-grade (G1/G2) carcinomas as well as in estrogen/progesterone and androgen receptor immunopositive tumors (p = 0.042, p = 0.016, p = 0.044, respectively). Favorable metastasis-free survival was observed in patients with pN0 and pN1 (vs. pN2+3) stage (p = 0.040) and with tumors characterized by low Ki-67LI (≤ 50% vs. > 50%) (p = 0.014). Patients with tumor androgen receptor immunonegativity (weak or lack of expression) or strong PTEN expression survived 3 years without metastases (p = 0.007).

The results of our study suggest that androgen receptor and PTEN status might be considered as indicators of trastuzumab sensitivity.
keywords:

HER2-overexpressing breast cancer, PTEN, PIK3CA mutations

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe